中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Application value of new liver function scoring models in radiofrequency ablation for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2020.09.041
  • Published Date: 2020-09-20
  • Comprehensive scoring models are one of the main methods for liver function evaluation and an important part of the treatment strategy for hepatocellular carcinoma. This article summarizes the value and limitations of traditional scoring models( Child-Turcotte-Pugh score and Model for End-Stage Liver Disease score) and new scoring models( albumin-bilirubin score,platelet-albumin-bilirubin score,and albumin-indocyanine green score) in radiofrequency ablation for hepatocellular carcinoma and points out that the new scoring models,especially platelet-albumin-bilirubin score,are advantageous.

     

  • [1] HO SY,LIU PH,HSU CY,et al. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation[J]. Sci Rep,2018,8(1):843.
    [2] FANG KC,SU CW,CHIOU YY,et al. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation:A propensity score matching analysis[J]. Eur Radiol,2017,27(6):2600-2609.
    [3] GIORGIO A,MEROLA MG,MONTESARCHIO L,et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis:Analysis of complications in a single centre over 20 years[J]. Br J Radiol,2017,90(1074):20160804.
    [4] PARK JG,PARK SY,TAK WY,et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma:An analysis of 1,843 ablations in 1,211 patients in a single centre:Experience over 10 years[J]. Clin Radiol,2017,72(8):692. e9-692.e15.
    [5] ZHANG L,GE NL,CHEN Y,et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma:10-year follow-up in Chinese patients[J]. Med Oncol,2015,32(3):77.
    [6] FONSECA AZ,SAAD WA,RIBEIRO JR MA. Complications after radiofrequency ablation of 233 hepatic tumors[J]. Oncology,2015,89(6):332-336.
    [7] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
    [8] LEE SK,SONG MJ,KIM SH,et al. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin(PALBI)and albumin-bilirubin(ALBI)grade:A nationwide cohort study[J]. PLo S One,2019,14(5):e0216173.
    [9] LIU PH,HSU CY,HSIA CY,et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era[J]. J Gastroenterol Hepatol,2017,32(4):879-886.
    [10] MALINCHOC M,KAMATH PS,GORDON FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology,2000,31(4):864-871.
    [11] SANTAMBROGIO R,BRUNO S,KLUGER MD,et al. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma[J]. Dig Liver Dis,2016,48(2):189-196.
    [12] LEE S,RHIM H,KIM YS,et al. Post-ablation des-gammacarboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma[J]. Liver Int,2016,36(4):580-587.
    [13] WANG Y,JIA JD. Evaluation of liver function and general condition before ablation and principles of medical treatment[J].Natl Med J China,2015,95(27):2160-2163.(in Chinese)王宇,贾继东.消融术前肝脏功能及全身情况评估与内科治疗原则[J].中华医学杂志,2015,95(27):2160-2163.
    [14] XIA F,LAI EC,LAU WY,et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis Brelated small hepatocellular carcinoma[J]. Ann Surg Oncol,2012,19(4):1284-1291.
    [15] QADAN M,GARDEN OJ,CORVERA CU,et al. Management of postoperative hepatic failure[J]. J Am Coll Surg,2016,222(2):195-208.
    [16] JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol,2015,33(6):550-558.
    [17] HIRAOKA A,KUMADA T,KUDO M,et al. Albumin-Bilirubin(ALBI)grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology:A comparison with the liver damage and Child-Pugh classifications[J]. Liver Cancer,2017,6(3):204-215.
    [18] NA SK,YIM SY,SUH SJ,et al. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma[J]. J Surg Oncol,2018,117(5):912-921.
    [19] CHONG CC,CHAN AW,WONG J,et al. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma[J]. Surgeon,2018,16(3):163-170.
    [20] KAO WY,SU CW,CHIOU YY,et al. Hepatocellular carcinoma:Nomograms based on the Albumin-Bilirubin grade to assess the outcomes of radiofrequency ablation[J]. Radiology,2017,285(2):670-680.
    [21] CHEN PC,CHIU NC,SU CW,et al. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy[J]. J Chin Med Assoc,2019,82(1):2-10.
    [22] OH IS,SINN DH,KANG TW,et al. Liver function assessment using Albumin-Bilirubin grade for patients with very earlystage hepatocellular carcinoma treated with radiofrequency ablation[J]. Dig Dis Sci,2017,62(11):3235-3242.
    [23] CHAN AW,KUMADA T,TOYODA H,et al. Integration of albumin-bilirubin(ALBI)score into Barcelona Clinic Liver Cancer(BCLC)system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2016,31(7):1300-1306.
    [24] CHAN AW,CHONG CC,MO FK,et al. Incorporating albuminbilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2017,32(1):221-228.
    [25] KOKUDO T,HASEGAWA K,AMIKURA K,et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma-the Albumin-Indocyanine Green Evaluation(ALICE)Grade[J]. PLo S One,2016,11(7):e0159530.
    [26] MIYAZAKI Y,KOKUDO T,AMIKURA K,et al. Albumin-indocyanine green evaluation grading system predicts post-hepatectomy liver failure for biliary tract cancer[J]. Dig Surg,2019,36(1):13-19.
    [27] RUSSOLILLO N,FORCHINO F,CONCI S,et al. Validation of the albumin-indocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albumin-bilirubin score[J]. J Hepatobiliary Pancreat Sci,2019,26(1):51-57.
    [28] JARUVONGVANICH V,SEMPOKUYA T,WONG L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?[J]. J Gastrointest Oncol,2018,9(4):750-761.
    [29] SHIN J,YU JH,JIN YJ,et al. Effective therapeutic options for elderly patients with hepatocellular carcinoma:A nationwide cohort study[J]. Medicine(Baltimore),2019,98(30):e16150.
    [30] TAKAMOTO T,SUGAWARA Y,HASHIMOTO T,et al. Evaluating the current surgical strategies for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol,2016,10(3):341-357.
  • Relative Articles

    [1]Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
    [2]Linna YUAN, Yihui CHEN, Hengbin NA, Jie LU, Ye LIU, Wu LI. Primary biliary cholangitis with metabolic associated fatty liver disease: Clinical features and risk factors[J]. Journal of Clinical Hepatology, 2024, 40(8): 1598-1604. doi: 10.12449/JCH240815
    [3]Di WU, Dahua DAI, Wenmei LIANG, Bao FU, Xiaoyun FU. Clinical features of acute pancreatitis in pregnancy and related risk factors[J]. Journal of Clinical Hepatology, 2024, 40(5): 1009-1015. doi: 10.12449/JCH240522
    [4]Chengsi ZHAO, Weijie YAO, Peng YUAN, Zuozheng WANG. Time distribution of risk factors for secondary pancreatic infection in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1686-1690. doi: 10.3969/j.issn.1001-5256.2022.07.044
    [5]Yu LIANG, Yuanhong ZHAO, Zheng LI. Recent advancement in research on intrahepatic cholangiocarcinoma: Risk factors and pathogenesis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2391-2395. doi: 10.3969/j.issn.1001-5256.2022.10.037
    [6]Yu LIU, Xue MEI, Yuyi ZHANG, Ying ZOU, Zhengguo ZHANG, Hongying GUO, Wei YUAN, Jiefei WANG, Zhiping QIAN. Clinical features and risk factors of acute hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2021, 37(3): 565-569. doi: 10.3969/j.issn.1001-5256.2021.03.013
    [7]Cao Yuan, Yao GuoXiang, Shi YiHai. An excerpt of international consensus guidelines for risk factors in chronic pancreatitis (2020)[J]. Journal of Clinical Hepatology, 2020, 36(8): 1720-1722. doi: 10.3969/j.issn.1001-5256.2020.08.008
    [8]Lin DongYi, Peng Bo, Zheng JingHui, Wang ZongYu, Li HanZhong, He JianBo, Li KeZhi, Wu GuoBin, Chen Chuang. Value of a logistic regression model based on the clinical features of liver cancer in judging the traditional Chinese medicine syndrome types of primary liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(6): 1293-1298. doi: 10.3969/j.issn.1001-5256.2020.06.021
    [9]Liu HongJin, Bao ChunMei, Bai WenLin, Li YinYin, Rong GuangHua, Lu YinYing, Chen Yan, Liu Ze, Cheng JiaMin, Ceng Zhen. Risk factors for infectious complications in primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1033-1037. doi: 10.3969/j.issn.1001-5256.2018.05.021
    [10]Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
    [11]Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
    [12]Wang ChunQiu, Ma YingCai, Zhu ZhiYong, Yuan Ling. Risk factors for pyogenic cholangitis in patients with common bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(1): 95-97. doi: 10.3969/j.issn.1001-5256.2017.01.020
    [13]Zhang Yu. High-risk factors for cholangitis after endoscopic sphincterotomy[J]. Journal of Clinical Hepatology, 2017, 33(7): 1316-1319. doi: 10.3969/j.issn.1001-5256.2017.07.022
    [14]YIERPAN Aishan, Gao Feng. Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2016, 32(1): 119-122. doi: 10.3969/j.issn.1001-5256.2016.01.022
    [15]Cui YanPing, Liu FengHua, Shi QingFeng, Zhao HongKui, Wang SiKui. Logistic regression analysis of prognostic factors in 106 acute-on-chronic liver failure patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2014, 30(10): 992-995. doi: 10.3969/j.issn.1001-5256.2014.10.005
    [16]Gao Rui, Liu ZhongJing, Chen Fei, Gao Lei, Jiang ChuanWu. Multivariate regression analysis of risk factors for HBV-related primary liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(4): 370-372. doi: 10.3969/j.issn.1001-5256.2014.04.021
    [17]Zhang ZhanQing, Lu Wei, Wang YanBing, Jia XiaoFang, Zhang LiJun, Ding RongRong, Zhou XinLan, Feng YanLing. Diagnosis of hepatic fibrosis in hepatitis B patients by logistic regression modeling based on plasma amino acid ratio and age[J]. Journal of Clinical Hepatology, 2013, 29(5): 330-335.
    [18]Lu: RiYing, Li ShiXiong, Wu JiZhou, Zhu YuJia, Fu ShaoPing. Development of a prognostic factors model for severe hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(10): 789-792.
    [19]Dou WeiJia, Zhou Lin, Wu KaiChun. Risk factors of chronic pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1180-1183.
  • Cited by

    Periodical cited type(3)

    1. 李炎,孙永岑. 专科护士主导的O2O多学科管理在肝硬化代偿期患者中的应用. 临床护理杂志. 2024(05): 39-43 .
    2. 郝志明,窦琴,包晓云. 基于PI3K/Akt信号通路探讨肝康片对四氯化碳致肝纤维化大鼠肝功能的保护机制. 现代消化及介入诊疗. 2020(02): 188-192 .
    3. 朱豫萌,朱丹燕,张国强. 中西药合用治疗慢性乙型病毒性肝炎疗效观察. 实用中医药杂志. 2019(09): 1101-1103 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 6.3 %FULLTEXT: 6.3 %META: 91.6 %META: 91.6 %PDF: 2.1 %PDF: 2.1 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.6 %其他: 7.6 %其他: 1.1 %其他: 1.1 %China: 0.2 %China: 0.2 %India: 0.2 %India: 0.2 %Reserved: 0.6 %Reserved: 0.6 %Richardson: 0.2 %Richardson: 0.2 %United States: 2.3 %United States: 2.3 %[]: 3.0 %[]: 3.0 %上海: 1.5 %上海: 1.5 %中卫: 0.2 %中卫: 0.2 %克洛滕: 0.2 %克洛滕: 0.2 %北京: 5.3 %北京: 5.3 %南宁: 0.2 %南宁: 0.2 %台州: 0.2 %台州: 0.2 %吉林: 0.8 %吉林: 0.8 %哈尔滨: 0.2 %哈尔滨: 0.2 %哥伦布: 0.4 %哥伦布: 0.4 %圣何塞: 0.4 %圣何塞: 0.4 %孟买: 0.2 %孟买: 0.2 %巴音郭楞: 0.2 %巴音郭楞: 0.2 %平顶山: 0.2 %平顶山: 0.2 %广州: 0.4 %广州: 0.4 %张家口: 2.7 %张家口: 2.7 %恩施: 0.2 %恩施: 0.2 %扬州: 0.2 %扬州: 0.2 %新加坡: 0.6 %新加坡: 0.6 %昌吉: 0.2 %昌吉: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.2 %杭州: 0.2 %武汉: 0.4 %武汉: 0.4 %泰州: 0.2 %泰州: 0.2 %洛杉矶: 0.2 %洛杉矶: 0.2 %温州: 0.2 %温州: 0.2 %湖州: 1.0 %湖州: 1.0 %福州: 0.4 %福州: 0.4 %纽卡斯尔: 0.2 %纽卡斯尔: 0.2 %美国加利福尼亚圣安娜: 0.2 %美国加利福尼亚圣安娜: 0.2 %芒廷维尤: 29.3 %芒廷维尤: 29.3 %芝加哥: 0.2 %芝加哥: 0.2 %莫斯科: 2.5 %莫斯科: 2.5 %衡水: 0.2 %衡水: 0.2 %衢州: 0.2 %衢州: 0.2 %西宁: 34.6 %西宁: 34.6 %重庆: 0.2 %重庆: 0.2 %长春: 0.4 %长春: 0.4 %长治: 0.2 %长治: 0.2 %其他其他ChinaIndiaReservedRichardsonUnited States[]上海中卫克洛滕北京南宁台州吉林哈尔滨哥伦布圣何塞孟买巴音郭楞平顶山广州张家口恩施扬州新加坡昌吉晋城杭州武汉泰州洛杉矶温州湖州福州纽卡斯尔美国加利福尼亚圣安娜芒廷维尤芝加哥莫斯科衡水衢州西宁重庆长春长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (566) PDF downloads(88) Cited by(3)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return